Literature DB >> 22271347

A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis.

Roberta D'Ambrosio1, Alessio Aghemo, Maria Grazia Rumi, Guido Ronchi, Maria Francesca Donato, Valerie Paradis, Massimo Colombo, Pierre Bedossa.   

Abstract

UNLABELLED: Although annular fibrosis is the hallmark of cirrhosis, other microscopic changes that affect liver function such as sinusoid capillarization or loss of metabolic zonation are common. A sustained virological response (SVR) may halt fibrosis deposition in hepatitis C virus (HCV)-infected patients, but its impact on the other cirrhosis-associated lesions is unknown. The aim of this study was to assess the impact of an SVR on cirrhosis-related histopathological features. Paired pre- and posttreatment liver biopsies from 38 HCV patients with cirrhosis with an SVR were analyzed. Fibrosis was staged using the METAVIR scoring system, and the area of fibrosis was measured using morphometry. Ductular proliferation, metabolic zonation, sinusoid capillarization, and hepatic stellate cell activation were assessed by anti-cytokeratin-7, anti-glutamine synthetase (GS), anti-cytochrome P4502E1 (CYP2E1), anti-CD34, and anti α-smooth muscle actin (αSMA). After 61 months from an SVR, cirrhosis regression was observed in 61%, and the collagen content decreased in 89%. Although periportal and lobular necroinflammation vanished, portal inflammation persisted in 66%. Ductular proliferation decreased in 92%. Before treatment, metabolic zonation was lost, as shown by GS and CYP2E1, in 71% and 88%, respectively, with normalization in 79% and 73%, after an SVR. Conversely, no changes in sinusoidal capillarization were observed after treatment, as assessed by CD34 (P = 0.41) and αSMA (P = 0.95). Finally, no differences in all the immunohistochemical scores emerged whether or not cirrhosis persisted.
CONCLUSION: Cirrhosis regression and decreased fibrosis are frequently observed among HCV patients with cirrhosis with an SVR. Despite ductular proliferation vanishing and lobular zonation restoration, portal inflammation and sinusoidal capillarization may not regress after viral eradication.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22271347     DOI: 10.1002/hep.25606

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  104 in total

Review 1.  Intestinal fibrosis: ready to be reversed.

Authors:  Giovanni Latella; Florian Rieder
Journal:  Curr Opin Gastroenterol       Date:  2017-07       Impact factor: 3.287

2.  Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience.

Authors:  Luca Rinaldi; Maria Guarino; Alessandro Perrella; Pia Clara Pafundi; Giovanna Valente; Luca Fontanella; Riccardo Nevola; Barbara Guerrera; Natalina Iuliano; Michele Imparato; Alessio Trabucco; Ferdinando Carlo Sasso; Filomena Morisco; Antonio Ascione; Guido Piai; Luigi Elio Adinolfi
Journal:  Dig Dis Sci       Date:  2019-04-01       Impact factor: 3.199

3.  Care of Patients Following Cure of Hepatitis C Virus Infection.

Authors:  Norah A Terrault
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-11

4.  The renin angiotensin system in liver and lung: impact and therapeutic potential in organ fibrosis.

Authors:  Amal Abdul-Hafez; Tarek Mohamed; Hanan Omar; Mohamed Shemis; Bruce D Uhal
Journal:  J Lung Pulm Respir Res       Date:  2018-02-27

5.  Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding.

Authors:  Andrew M Moon; Pamela K Green; Don C Rockey; Kristin Berry; George N Ioannou
Journal:  Aliment Pharmacol Ther       Date:  2019-11-27       Impact factor: 8.171

6.  Frontiers in the treatment of hepatitis C virus infection.

Authors:  Joseph Ahn; Steven L Flamm
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-02

7.  Epithelial VEGF signaling is required in the mouse liver for proper sinusoid endothelial cell identity and hepatocyte zonation in vivo.

Authors:  Teagan J Walter; Ashley E Cast; Kari A Huppert; Stacey S Huppert
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-03-20       Impact factor: 4.052

Review 8.  Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality.

Authors:  Nobuyuki Toshikuni; Tomiyasu Arisawa; Mikihiro Tsutsumi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 9.  Noninvasive diagnosis of cirrhosis: a review of different imaging modalities.

Authors:  Riccardo De Robertis; Mirko D'Onofrio; Emanuele Demozzi; Stefano Crosara; Stefano Canestrini; Roberto Pozzi Mucelli
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 10.  The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment.

Authors:  Brian P Lam; Thomas Jeffers; Zahra Younoszai; Yousef Fazel; Zobair M Younossi
Journal:  Therap Adv Gastroenterol       Date:  2015-09       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.